Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis.
van dH, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. van dH, et al. Among authors: purcaru o. Value Health. 2014 Nov;17(7):A387. doi: 10.1016/j.jval.2014.08.2653. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200883 Free article. No abstract available.
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Kavanaugh A, et al. Among authors: purcaru o. Ann Rheum Dis. 2015 Jan;74(1):44-51. doi: 10.1136/annrheumdis-2014-205198. Epub 2014 Jun 18. Ann Rheum Dis. 2015. PMID: 24942382 Free PMC article. Clinical Trial.
Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Osterhaus JT, Purcaru O. Osterhaus JT, et al. Among authors: purcaru o. Arthritis Res Ther. 2014 Aug 6;16(4):R164. doi: 10.1186/ar4680. Arthritis Res Ther. 2014. PMID: 25099160 Free PMC article. Clinical Trial.
Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study.
Westhovens R, Ravelingien I, Vandevyvere K, Pansar I, Purcaru O, Kumke T, Gyselbrecht L. Westhovens R, et al. Among authors: purcaru o. Acta Clin Belg. 2019 Oct;74(5):342-350. doi: 10.1080/17843286.2018.1509923. Epub 2018 Aug 30. Acta Clin Belg. 2019. PMID: 30160189
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: purcaru o. Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10. Ann Rheum Dis. 2017. PMID: 27165179 Free PMC article. Clinical Trial.
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H. Smolen JS, et al. Among authors: purcaru o. Ann Rheum Dis. 2015 May;74(5):843-50. doi: 10.1136/annrheumdis-2013-204632. Epub 2014 Jan 15. Ann Rheum Dis. 2015. PMID: 24431394 Free PMC article. Clinical Trial.
24 results